What Happened
On March 5, 2026, the FDA issued a Complete Response Letter (CRL) to Chiesi Global Rare Diseases regarding their New Drug Application for idebenone as a treatment for Leber's Hereditary Optic Neuropathy.
A CRL is not a permanent rejection. It's the FDA's formal way of saying: "We can't approve this in its current form — here's what you need to fix." But make no mistake — it's a significant setback, and patients deserve a straight answer about what it means.
- More clinical data required — The agency wants additional evidence from adequate and well-controlled studies to further establish safety and effectiveness. In plain English: the Phase 3 RHODOS trial and Phase 4 LEROS data weren't enough to clear the bar for US approval.
- Manufacturing and chemistry issues — There were unresolved questions related to a referenced Drug Master File that need to be addressed before the application can move forward.
- No new safety concerns raised — This is important. The FDA did not raise any new red flags around idebenone's safety profile. The issue is evidence and manufacturing standards, not the drug hurting people.
Chiesi has stated they are reviewing the contents of the letter and plan to work with the FDA to determine next steps. They have not committed to a resubmission timeline.
What This Doesn't Mean
Before the fear sets in, let's be clear about what this decision is not.
It does not mean idebenone doesn't work. The RHODOS trial and its long-term LEROS extension — together representing the largest body of prospective evidence on idebenone in LHON — showed meaningful visual acuity preservation in patients who received treatment within the acute phase. The drug is already approved as Raxone® in the EU, UK, Switzerland, Israel, South Korea, and several other countries based on that same body of evidence. The FDA simply wants more data than what currently exists.
It does not mean idebenone is unsafe. Again: no new safety concerns were identified. If you are currently taking idebenone, there is no reason based on this decision to stop.
It does not mean the fight is over. Chiesi can resubmit. The FDA's CRL process is designed to be a dialogue, not a door slamming shut. That said, the path forward likely means years — not months — of additional clinical work before another submission is possible.
What This Means for the Supplement Market
Here's something the clinical press releases won't tell you: this decision has an important practical implication for patients in the United States who have been sourcing idebenone as a dietary supplement.
Under FDA regulations, if a substance receives full drug approval in the US, the agency gains grounds to restrict or prohibit its sale as a dietary supplement — similar to what happened with CBD after the approval of Epidiolex. That risk was real while Chiesi's application was pending.
With the CRL issued, that clock has stopped — for now. Idebenone remains in the regulatory gray zone as a supplement, which means it continues to be available through supplement retailers in the United States.
This is cold comfort, because the idebenone quality problem is still very much a problem. The majority of idebenone sold in the US supplement market is sourced from overseas manufacturers with little to no third-party verification of purity or potency. The 900mg/day clinical dose used in the trials is meaningless if what's in the capsule isn't what's on the label. If you're going to take idebenone, source matters more than price. Certificate of Analysis (CoA), third-party testing, and US-based manufacturing should be non-negotiable.
The Bigger Picture: Gene Therapy Is a Separate Track
While the idebenone news is discouraging, it's worth separating the FDA's CRL from the broader treatment landscape for LHON — because there's a separate and genuinely promising story developing in parallel.
Research into intravitreal gene therapy targeting the 11778 mutation has produced meaningful results in clinical trials. This is a different mechanism entirely — rather than supplementing mitochondrial function as idebenone does, gene therapy attempts to correct the underlying genetic defect in retinal ganglion cells. The trials are ongoing, access is limited, and timelines are uncertain — but the science is real and moving forward.
For patients in the acute phase right now, gene therapy is not immediately accessible in the US — but knowing it exists, what the evidence shows, and how to ask your neuro-ophthalmologist about clinical trial eligibility matters. I'll be covering the gene therapy landscape in detail in an upcoming post.
What You Should Actually Do Right Now
If you or someone you love has LHON, here's the practical framework in the wake of this news:
Don't stop idebenone if you're currently taking it
No new safety data came out of this decision. If you're in or near the acute phase, the EU/UK approval and the LEROS trial evidence remain valid reasons to continue — under your physician's guidance.
Focus on timing above all else
The strongest signal in the idebenone research is that early treatment matters. The further you get from the acute phase, the smaller the potential benefit. If you're newly diagnosed, this is not the moment to wait and see what the FDA does next.
Build the mitochondrial foundation
Idebenone isn't the only tool. A holistic mitochondrial support protocol — CoQ10 ubiquinol, riboflavin (B2), alpha lipoic acid, NAD+ precursors — targets the same energy production pathways and has a strong safety profile. This isn't a replacement for idebenone; it's the broader foundation that idebenone works within.
Eliminate the known triggers immediately
Smoking and tobacco use are the most clearly documented environmental accelerators of LHON progression. Excessive alcohol and certain medications that interfere with mitochondrial function are also documented risk factors. Your neuro-ophthalmologist should be walking you through this list.
Find a specialist — not just any ophthalmologist
Most general ophthalmologists have never seen an LHON patient. The decisions you make in the first 12 months significantly influence your trajectory. You need a neuro-ophthalmologist with LHON experience. We're working on a resource for exactly this.
My Take
I've been in this community for over two decades. I know what it feels like to watch a treatment that works for people in Europe be unavailable here — not because it's unsafe, not because it doesn't work, but because the evidentiary bar is different and the commercial pathway for rare disease drugs in the US is genuinely difficult.
The FDA's CRL is frustrating. It is not a death blow.
What this moment calls for is exactly what this site is built around: a community that is deeply informed, not dependent on a single regulatory outcome, proactive about every legitimate tool available, and connected enough to support each other through the uncertainty.
The fight for a US-approved LHON treatment isn't over. Chiesi will resubmit. Gene therapy trials are advancing. And in the meantime, there is more you can do today — with what exists right now — than most people newly diagnosed with this disease ever learn about.
That's why this site exists.
Have questions? The LHON AI is here.
Trained on the clinical research and available around the clock — because a diagnosis doesn't wait for business hours.
Talk to the LHON AI Join the CommunityThis content is for informational purposes only and does not constitute medical advice. Always consult a qualified physician — ideally a neuro-ophthalmologist with LHON experience — before making treatment decisions. Sources: Chiesi Global Rare Diseases press release (March 5, 2026); Ophthalmology Times; Optometry Times; BioWorld.